

## Advanced Therapies - November 2023

Date	Company	Cluster	Technology / Segment	About	Investment (\$ Million USD)	Financing Type	Investors / Information
11-09	Cargo Therapeutics	San Francisco	Cell Therapy	CARGO Therapeutics develops an adoptive cell therapy to benefit patients from potentially curative treatment options.	\$281.00	IPO	IPO of 18,750,000 shares of its common stock at a public offering price of \$15.00 per share
11-15	Arcellx	Washington D.C. / Baltimore	Cell Therapy	Arcellx is a clinical-stage biotechnology company that provides patients with immune cell therapies.	\$200.00	Post IPO Equity	Kite / Gilead
11-28	Verve Therapeutics	Boston	Gene Therapy	Verve Therapeutics is a genetic medicine firm that is developing treatments for cardiovascular disease.	\$148.00	Post IPO Equity	12.5 million shares of its common stock at \$10 per share. Along with the stock offering 2.2M shares to Eli Lilly at the \$10 per share price. This sale will bring in \$23 million for the company. Expects combined gross proceeds of \$148 million for the two deals.
11-02	Lexeo Therapeutic	New York	Gene Therapy	LEXEO Therapeutics utilizes gene therapy to treat genetically defined cardiovascular and central nervous system diseases.	\$100.00	IPO	Lexeo has secured \$100M to back two clinical-stage programs and other initiatives in its pipeline. The company had to reduce the price of its IPO, it originally intended to offer 9M shares in the \$13 to \$15 range, potentially raising \$126 million at the midpoint, Lexeo ultimately offered 9.09M shares at \$11 / Share
11-15	T-Therapeutics	Europe - UK	Cell Therapy	T-Therapeutics is a next-generation T cell receptor (TCR) company spun off from the University of Cambridge.	\$59.00	Series A	Sofinnova Partners, F-Prime Capital, Digitalis Ventures and Cambridge Innovation Capital.
11-15	Smart Immune	Europe	Cell Therapy	Smart Immune is a biotech company that helps fight against cancer and infection by providing a thymus-empowered T-cell therapy platform.	\$54.00	Series A	Mural Oncology is spinning out of Alkermes with \$275 million and a lead immunotherapy candidate already in two studies in mucosal melanoma and ovarian cancer. On top of the funding, Alkermes is also distributing Mural stock to its shareholders — one Mural share for every 10 Alkermes shares they own.
11-21	Quotient Therapeutics	Europe - UK	Gene Therapy		\$50.00	Venture	Flagship Pioneering
11-15	NTx	New Mexico	mRna	Nature's Toolbox is a biotechnology company that provides a proprietary host-independent biological manufacturing and development platform.	\$47.50	Series B	Anzu Partners and long-standing investor BlueStone Venture Partners
11-01	Bowang Pharmaceutical	China	mRna	Bowang Pharmaceutical is an RNAi drug research and development platform focused on siRNA drug development.	\$41.20	Series A	SDIC Fund Management, Huagai Capital, Trinity Innovation Fund, Yuanxi Haihe Fund
11-08	Ascidian Therapeutics	Boston	Gene Therapy	Ascidian Therapeutics is a biotechnology company that focuses on medical and clinical gene therapy.	\$40.00	Series A	Apple Tree Partners
11-15	CellProthera	Europe	Cell Therapy	CellProthera plans to raise around \$30 million in its first major fundraise to help advance its lead regenerative cell therapy program for patients who have recently experienced heart attacks into registrational development, Endpoints News has learned.	\$30.00	Venture	
11-14	Vittoria Biotherapeutics	Philadelphia	Cell Therapy	Vittoria Biotherapeutics is a gene-edited cell therapeutics company.	\$15.00	Venture	Valley Forge Investment Corporation, includes investments from institutions such as Agent Capital, Tellus BioVentures, the University of Pennsylvania, BioAdvance, The New York Blood Center, and The Leukemia & Lymphoma Society Therapy Acceleration Program (LLS TAP)
11-16	Gradalis	Texas	Cell Therapy	Gradalis is engaged in manufacturing immunotherapy for the treatment of cancer.	\$9.90	Grant	Cancer Prevention and Research Institute
11-28	Harness Therapeutics	Europe - UK	mRna	Harness Therapeutics is a developer of a platform for physiological upregulation of proteins using targeted translation enhancers, SINEUPs.	\$5.01	Seed	SV Health Investors

Date	Company	Cluster	Technology / Segment	About	Investment (\$ Million USD)	Financing Type	Investors / Information
11-22	Linio Biotech	Europe	Tissue Engineering	Linio Biotech is a biotechnology platform company developing novel tissue product Tience® that regenerates healthy skin.	\$4.50	Seed	
11-02	BiomEdit	Indiana	Microbiome	Microbiome Innovation for Animal Health	\$4.50	Grant	Bill and Melinda Gates Foundation
11-13	Ray Therapeutics	San Diego	Gene Therapy	Ray Therapeutics is a biotech company that develops optogenetic gene therapies for patients with blinding diseases.	\$4.00	Grant	CRIM
11-16	4D Molecular Therapeutics	San Francisco	Gene Therapy	4D Molecular Therapeutics designs, develops, and commercializes transformative gene therapeutic products for unmet medical conditions.	\$2.80	Grant	Cystic Fibrosis
11-20	RION	Minnesota	Exsome	RION is a clinical-stage regenerative medicine company.	\$2.40	Grant	Department of Defense - U.S. Army Medical Research Institute for Chemical Defense (ICD)
11-30	Transcode Therapeutics	Boston	mRna	TransCode is an RNA oncology company created on the belief that cancer can be more effectively treated using RNA therapeutics. Using its iron oxide nanoparticle delivery platform, the company has created a portfolio of drug candidates designed to target a variety of tumor types with the objective of significantly improving patient outcomes.	\$1.20	Post IPO Equity	
11-22	Linio Biotech	Europe	Tissue Engineering	Linio Biotech is a biotechnology platform company developing novel tissue product Tience® that regenerates healthy skin.	\$1.00	Grant	Business Finland
11-06	Phycin	Washington D.C. / Baltimore	Cell Therapy		\$0.40	Grant	Maryland Stem Cell Research Fund

<b>Advanced Therapies Financings</b>		
Type	Total Raised	# of Deals
Gene Therapy	\$344.8	6
Microbiome	\$4.5	1
Cell Therapy	\$649.3	8
mRna	\$94.9	4
Exsome	\$2.4	1
Tissue Engineering	\$5.5	2
<b>Total</b>	<b>\$1,101.4</b>	<b>22</b>